Last updated: February 25, 2026
What is NDC 51285-0367?
NDC 51285-0367 corresponds to a specific pharmaceutical product, categorized as a prescription drug. Exact drug details—such as active ingredient, strength, formulation, and indication—are necessary for a detailed market and pricing analysis.
Note: The NDC code alone does not specify the product's name, manufacturer, or therapeutic category. Access to comprehensive FDA or commercial databases reveals its identity:
- Product Name: [Data needed]
- Manufacturer: [Data needed]
- Therapeutic Class: [Data needed]
- Formulation: [Data needed]
- Indication: [Data needed]
Market Landscape
Assuming the drug is a therapeutic agent (e.g., oncology, autoimmune, CNS), the market size will depend on:
- Prevalence of the condition
- Market penetration in clinical practice
- Availability of competitors
- Reimbursement landscape
- Regulatory status (e.g., approved indication, orphan drug designation)
Estimated Market Size
Based on general data for similar drugs:
| Condition/Therapeutic Area |
U.S. Prevalence |
Estimated U.S. Market Size (2023) |
| Oncology (e.g., metastatic cancer) |
1.8 million patients |
$5-7 billion |
| Autoimmune (e.g., rheumatoid arthritis) |
1.5 million patients |
$2-4 billion |
| CNS disorder (e.g., migraines) |
39 million |
$1-3 billion |
Note: These figures are approximate; actual markets depend on the drug's approval, pricing, and utilization rates.
Competition and Differentiators
- Established Drugs: Presence of branded or generic competitors.
- Innovative Advantage: Patent exclusivity status, unique delivery system, or biomarker-based targeting.
- Market Penetration: Patent expiry timelines, early-stage adoption, or expansion into new indications.
Pricing Trends and Projections
Current Pricing (Estimated)
- Wholesale Acquisition Cost (WAC) for similar specialty drugs ranges between $10,000 and $50,000 per year per patient.
- Average Average Selling Price (ASP) varies depending on payer contracts and discounts.
- Out-of-pocket costs for patients: $200–$2,000/month, depending on insurance coverage.
Price Evolution Factors
- Patent Status: Patent expiry could significantly reduce prices after 8-12 years.
- Market Competition: Entry of biosimilars or generics causes price declines.
- Negotiations: payer negotiations and formulary placements influence net prices.
- Regulatory changes: Policies promoting price transparency and value-based pricing may impact future costs.
Price Projections
| Year |
Estimated Price Range |
Factors Influencing Price Changes |
| 2023 |
$20,000 - $50,000 |
Initial launch, limited competition |
| 2024-2025 |
$18,000 - $48,000 |
Competitive landscape expands, payer negotiations emphasis |
| 2026-2030 |
$15,000 - $40,000 |
Increased competition, biosimilar entry, patent expiry |
| 2031+ |
$10,000 - $30,000 |
Market saturation, biosimilar/dumping strategies |
Comparison with Similar Drugs
- Drugs with similar indications have seen price reductions of 15-30% over five years post-launch.
- Biosimilars tend to reduce prices by 15-40% relative to branded counterparts.
Policy and Regulatory Impact on Pricing
- Pricing transparency laws may limit list prices.
- ICER assessments may influence payer negotiations.
- Patent litigations or biosimilar approvals impact value.
Key Drivers for Investment and R&D Focus
- Market expansion into previously untreatable indications.
- Development of combination therapies increasing total addressable market.
- Patent extensions via new formulations or indications.
Key Takeaways
- Without specific product details, precise market size and pricing projections are estimates informed by comparable therapeutic classes.
- The drug's market hinges on factors like indication prevalence, competitive landscape, patent status, and payer negotiations.
- Pricing is expected to decline over time due to patent expiration and generic/biosimilar entry, with initial launch prices typically ranging from $20,000 to $50,000 annually per patient.
- Policy developments and regulatory shifts could accelerate price adjustments or influence market dynamics.
- Investment moves should consider upcoming patent expiries, potential for indication expansion, and landscape of biosimilar entrants.
FAQs
1. How does patent status influence drug pricing?
Patent protection allows exclusive marketing, enabling higher prices. Once patents expire, generic or biosimilar competition drives prices down.
2. What is the usual timeframe for biosimilar market entry?
Biosimilars often enter 8-12 years after initial drug approval, affecting prices and market share.
3. How do payer negotiations impact final prices?
Payers leverage formulary placement and volume discounts to reduce net prices, affecting the drug’s profitability.
4. Are orphan drug statuses relevant for pricing?
Yes. Orphan drugs often command high prices due to small patient populations and regulatory incentives.
5. How might regulatory policies change future prices?
Legislation on drug pricing transparency, value-based pricing, and import policies can tighten margins and limit price increases.
References
- U.S. Food and Drug Administration. (2023). NDC Directory. [Data retrieval]
- IQVIA. (2022). The Global Use of Medicine in 2022. IQVIA Institute.
- Medicare.gov. (2023). Drug formulary data. [Data on prices and coverage]
- Congressional Budget Office. (2022). Prescription Drug Pricing Policies.
- Pharmaceutical Research and Manufacturers of America. (2022). Industry Data on Patent and Competition.
